Patient Support Programs: A Hidden AE Volume Source

This module has covered risk minimisation measures as documented commitments in an RMP — educational materials, restricted programs, monitoring requirements. Patient Support Programs are one of the most common real-world implementations of that concept, and one of the least understood from a PV operations standpoint until a team has already been through one.

A PSP might be a nurse-staffed adherence hotline, a mobile app that reminds patients to take a medication and lets them log symptoms, or a financial-assistance program that involves regular contact with patients. Every one of those touchpoints is also, structurally, a channel for a patient to report an adverse event — and under GVP Module VI, any AE mentioned through a PSP counts as a solicited report, which carries its own documentation and causality-assessment conventions distinct from an unsolicited spontaneous report.

The operational risk is volume, and it’s frequently underestimated because PSPs are usually designed by patient services, marketing, or medical affairs teams focused on adherence and access — not by PV, and not always with PV consulted early. When a PSP launches and patients start actually using it, the AE volume can arrive all at once, and a meaningful share of it tends to be serious and unlabeled, which under expedited reporting rules puts a hard clock on processing it — exactly the kind of clock this course has covered since Module 1.

The fix is structural, not reactive: PV involvement in PSP design from the start, realistic volume forecasting before launch (not after), and a defined intake and triage pathway for PSP-originated reports before the first patient ever calls in. A PSP’s value as a risk-minimisation measure and its cost as an AE-volume source are two sides of the same benefit-risk calculation — not separate conversations.